258 related articles for article (PubMed ID: 19229700)
1. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.
Vanaja DK; Ehrich M; Van den Boom D; Cheville JC; Karnes RJ; Tindall DJ; Cantor CR; Young CY
Cancer Invest; 2009 Jun; 27(5):549-60. PubMed ID: 19229700
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of CpG islands in primary and metastatic human prostate cancer.
Yegnasubramanian S; Kowalski J; Gonzalgo ML; Zahurak M; Piantadosi S; Walsh PC; Bova GS; De Marzo AM; Isaacs WB; Nelson WG
Cancer Res; 2004 Mar; 64(6):1975-86. PubMed ID: 15026333
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer--novel predictor of biochemical recurrence after radical surgery.
Mitsui Y; Shiina H; Hiraki M; Arichi N; Hiraoka T; Sumura M; Honda S; Yasumoto H; Igawa M
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):487-96. PubMed ID: 22246902
[TBL] [Abstract][Full Text] [Related]
4. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.
Ellinger J; Bastian PJ; Jurgan T; Biermann K; Kahl P; Heukamp LC; Wernert N; Müller SC; von Ruecker A
Urology; 2008 Jan; 71(1):161-7. PubMed ID: 18242387
[TBL] [Abstract][Full Text] [Related]
5. [GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer].
Bastian PJ; Nakayama M; De Marzo AM; Nelson WG
Urologe A; 2004 May; 43(5):573-9. PubMed ID: 15029477
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.
Chuang CK; Chu DC; Tzou RD; Liou SI; Chia JH; Sun CF
Cancer Detect Prev; 2007; 31(1):59-63. PubMed ID: 17291695
[TBL] [Abstract][Full Text] [Related]
7. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma.
Jerónimo C; Henrique R; Campos PF; Oliveira J; Caballero OL; Lopes C; Sidransky D
J Clin Pathol; 2003 Jan; 56(1):52-5. PubMed ID: 12499435
[TBL] [Abstract][Full Text] [Related]
8. [Restriction landmark genomic scanning for screening aberrant CpG methylations in prostate cancer].
Li D; Xu Z; Liu J; Pu X; Luo Y; Zheng X
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jan; 36(1):103-8. PubMed ID: 26806748
[TBL] [Abstract][Full Text] [Related]
9. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.
Nakayama M; Gonzalgo ML; Yegnasubramanian S; Lin X; De Marzo AM; Nelson WG
J Cell Biochem; 2004 Feb; 91(3):540-52. PubMed ID: 14755684
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
[TBL] [Abstract][Full Text] [Related]
11. Global methylation profiling for risk prediction of prostate cancer.
Mahapatra S; Klee EW; Young CY; Sun Z; Jimenez RE; Klee GG; Tindall DJ; Donkena KV
Clin Cancer Res; 2012 May; 18(10):2882-95. PubMed ID: 22589488
[TBL] [Abstract][Full Text] [Related]
12. A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia.
Basu S; Majumder S; Bhowal A; Ghosh A; Naskar S; Nandy S; Mukherjee S; Sinha RK; Basu K; Karmakar D; Banerjee S; Sengupta S
PLoS One; 2015; 10(5):e0125560. PubMed ID: 25938433
[TBL] [Abstract][Full Text] [Related]
13. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
Ellinger J; Haan K; Heukamp LC; Kahl P; Büttner R; Müller SC; von Ruecker A; Bastian PJ
Prostate; 2008 Jan; 68(1):42-9. PubMed ID: 18004747
[TBL] [Abstract][Full Text] [Related]
14. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
15. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids.
Goessl C; Krause H; Müller M; Heicappell R; Schrader M; Sachsinger J; Miller K
Cancer Res; 2000 Nov; 60(21):5941-5. PubMed ID: 11085508
[TBL] [Abstract][Full Text] [Related]
16. [Genome-wide analysis of DNA methylation in prostate cancer using the technology of Infinium HumanMethylation450 BeadChip (HM450)].
Babalyan KA; Sultanov R; Generozov EV; Zakharzhevskaya NB; Sharova EI; Peshkov MN; Vasilev AO; Govorov AV; Pushkar DY; Prilepskaya EA; Danilenko SA; Babikova EA; Larin AK; Govorun VM
Vopr Onkol; 2016; 62(1):122-32. PubMed ID: 30444590
[TBL] [Abstract][Full Text] [Related]
17. Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer.
Mostafavi-Pour Z; Kianpour S; Dehghani M; Mokarram P; Torabinejad S; Monabati A
Pathol Oncol Res; 2015 Sep; 21(4):921-7. PubMed ID: 25743258
[TBL] [Abstract][Full Text] [Related]
18. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Pookot D; Li LC; Tabatabai ZL; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Int J Cancer; 2005 Aug; 116(2):174-81. PubMed ID: 15800905
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
[TBL] [Abstract][Full Text] [Related]
20. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia.
Kang GH; Lee S; Lee HJ; Hwang KS
J Pathol; 2004 Feb; 202(2):233-40. PubMed ID: 14743506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
